174 related articles for article (PubMed ID: 36840413)
1. An integrative epigenomic approach identifies ELF3 as an oncogenic regulator in ASCL1-positive neuroendocrine carcinoma.
Horie M; Tanaka H; Suzuki M; Sato Y; Takata S; Takai E; Miyashita N; Saito A; Nakatani Y; Yachida S
Cancer Sci; 2023 Jun; 114(6):2596-2608. PubMed ID: 36840413
[TBL] [Abstract][Full Text] [Related]
2. ASCL1 regulates super-enhancer-associated miRNAs to define molecular subtypes of small cell lung cancer.
Miyakawa K; Miyashita N; Horie M; Terasaki Y; Tanaka H; Urushiyama H; Fukuda K; Okabe Y; Ishii T; Kuwahara N; Suzuki HI; Nagase T; Saito A
Cancer Sci; 2022 Nov; 113(11):3932-3946. PubMed ID: 35789143
[TBL] [Abstract][Full Text] [Related]
3. ELF3 activated by a superenhancer and an autoregulatory feedback loop is required for high-level HLA-C expression on extravillous trophoblasts.
Li Q; Meissner TB; Wang F; Du Z; Ma S; Kshirsagar S; Tilburgs T; Buenrostro JD; Uesugi M; Strominger JL
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33622787
[TBL] [Abstract][Full Text] [Related]
4. E26 transformation (ETS)‑specific related transcription factor‑3 (ELF3) orchestrates a positive feedback loop that constitutively activates the MAPK/Erk pathway to drive thyroid cancer.
Chen H; Chen W; Zhang X; Hu L; Tang G; Kong J; Wang Z
Oncol Rep; 2019 Jan; 41(1):570-578. PubMed ID: 30365150
[TBL] [Abstract][Full Text] [Related]
5. A Transcriptional Regulatory Loop of Master Regulator Transcription Factors, PPARG, and Fatty Acid Synthesis Promotes Esophageal Adenocarcinoma.
Ma S; Zhou B; Yang Q; Pan Y; Yang W; Freedland SJ; Ding LW; Freeman MR; Breunig JJ; Bhowmick NA; Pan J; Koeffler HP; Lin DC
Cancer Res; 2021 Mar; 81(5):1216-1229. PubMed ID: 33402390
[TBL] [Abstract][Full Text] [Related]
6. Significance of achaete-scute complex homologue 1 (ASCL1) in pulmonary neuroendocrine carcinomas; RNA sequence analyses using small cell lung cancer cells and Ascl1-induced pulmonary neuroendocrine carcinoma cells.
Kudoh S; Tenjin Y; Kameyama H; Ichimura T; Yamada T; Matsuo A; Kudo N; Sato Y; Ito T
Histochem Cell Biol; 2020 Jun; 153(6):443-456. PubMed ID: 32170367
[TBL] [Abstract][Full Text] [Related]
7. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers.
Augustyn A; Borromeo M; Wang T; Fujimoto J; Shao C; Dospoy PD; Lee V; Tan C; Sullivan JP; Larsen JE; Girard L; Behrens C; Wistuba II; Xie Y; Cobb MH; Gazdar AF; Johnson JE; Minna JD
Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14788-93. PubMed ID: 25267614
[TBL] [Abstract][Full Text] [Related]
8. ETS transcription factor ESE1/ELF3 orchestrates a positive feedback loop that constitutively activates NF-κB and drives prostate cancer progression.
Longoni N; Sarti M; Albino D; Civenni G; Malek A; Ortelli E; Pinton S; Mello-Grand M; Ostano P; D'Ambrosio G; Sessa F; Garcia-Escudero R; Thalmann GN; Chiorino G; Catapano CV; Carbone GM
Cancer Res; 2013 Jul; 73(14):4533-47. PubMed ID: 23687337
[TBL] [Abstract][Full Text] [Related]
9. A transcriptional repressive role for epithelial-specific ETS factor ELF3 on oestrogen receptor alpha in breast cancer cells.
Gajulapalli VN; Samanthapudi VS; Pulaganti M; Khumukcham SS; Malisetty VL; Guruprasad L; Chitta SK; Manavathi B
Biochem J; 2016 Apr; 473(8):1047-61. PubMed ID: 26920025
[TBL] [Abstract][Full Text] [Related]
10. Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma.
Enfield KSS; Marshall EA; Anderson C; Ng KW; Rahmati S; Xu Z; Fuller M; Milne K; Lu D; Shi R; Rowbotham DA; Becker-Santos DD; Johnson FD; English JC; MacAulay CE; Lam S; Lockwood WW; Chari R; Karsan A; Jurisica I; Lam WL
Nat Commun; 2019 Nov; 10(1):5438. PubMed ID: 31780666
[TBL] [Abstract][Full Text] [Related]
11. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of ELF3 facilitates cell growth and metastasis through PI3K/Akt and ERK signaling pathways in non-small cell lung cancer.
Wang H; Yu Z; Huo S; Chen Z; Ou Z; Mai J; Ding S; Zhang J
Int J Biochem Cell Biol; 2018 Jan; 94():98-106. PubMed ID: 29208568
[TBL] [Abstract][Full Text] [Related]
13. ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.
Yeung TL; Leung CS; Wong KK; Gutierrez-Hartmann A; Kwong J; Gershenson DM; Mok SC
Oncotarget; 2017 Mar; 8(10):16951-16963. PubMed ID: 28199976
[TBL] [Abstract][Full Text] [Related]
14. E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma.
Gondkar K; Patel K; Krishnappa S; Patil A; Nair B; Sundaram GM; Zea TT; Kumar P
Cancer Biomark; 2019; 25(2):223-232. PubMed ID: 31104013
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of TTF-1 binding DNA regions in small-cell lung cancer and non-small-cell lung cancer.
Hokari S; Tamura Y; Kaneda A; Katsura A; Morikawa M; Murai F; Ehata S; Tsutsumi S; Ishikawa Y; Aburatani H; Kikuchi T; Miyazono K; Koinuma D
Mol Oncol; 2020 Feb; 14(2):277-293. PubMed ID: 31782890
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System.
Yachida S; Totoki Y; Noë M; Nakatani Y; Horie M; Kawasaki K; Nakamura H; Saito-Adachi M; Suzuki M; Takai E; Hama N; Higuchi R; Hirono S; Shiba S; Kato M; Furukawa E; Arai Y; Rokutan H; Hashimoto T; Mitsunaga S; Kanda M; Tanaka H; Takata S; Shimomura A; Oshima M; Hackeng WM; Okumura T; Okano K; Yamamoto M; Yamaue H; Morizane C; Arihiro K; Furukawa T; Sato T; Kiyono T; Brosens LAA; Wood LD; Hruban RH; Shibata T
Cancer Discov; 2022 Mar; 12(3):692-711. PubMed ID: 34880079
[TBL] [Abstract][Full Text] [Related]
17. LncRNA ELF3-AS1 Promotes Non-Small Cell Lung Cancer Cell Invasion and Migration by Downregulating miR-212.
Zhang Z; Nong L; Chen ML; Gu XL; Zhao WW; Liu MH; Cheng WW
Cancer Biother Radiopharm; 2022 Mar; 37(2):119-124. PubMed ID: 32598181
[TBL] [Abstract][Full Text] [Related]
18. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
19. Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.
Mesquita B; Lopes P; Rodrigues A; Pereira D; Afonso M; Leal C; Henrique R; Lind GE; Jerónimo C; Lothe RA; Teixeira MR
Breast Cancer Res Treat; 2013 Feb; 138(1):37-45. PubMed ID: 23329352
[TBL] [Abstract][Full Text] [Related]
20. E74-Like Factor 3 Is a Key Regulator of Epithelial Integrity and Immune Response Genes in Biliary Tract Cancer.
Suzuki M; Saito-Adachi M; Arai Y; Fujiwara Y; Takai E; Shibata S; Seki M; Rokutan H; Maeda D; Horie M; Suzuki Y; Shibata T; Kiyono T; Yachida S
Cancer Res; 2021 Jan; 81(2):489-500. PubMed ID: 33293429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
